Katrina Blazek

Ms. Katrina Blazek


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2011 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
TKThomas Krausgruber
Thomas Krausgruber
KBKatrina Blazek
Katrina Blazek
TSTim Smallie
Tim Smallie
SASaba Alzabin
Saba Alzabin
HLHelen Lockstone
Helen Lockstone
IUIrina A Udalova
Irina A Udalova

1 March 2008 in Genes & Development
Verified
Journal Article
Open access
PDF file
SOSamantha Oakes
Samantha Oakes
MNMatthew J. Naylor
Matthew J. Naylor
MAMarie-Liesse Asselin-Labat
Marie-Liesse Asselin-Labat
KBKatrina Blazek
Katrina Blazek
MGMargaret Gardiner-Garden
Margaret Gardiner-Garden
COChristopher J. Ormandy
Christopher J. Ormandy
Hormonal cues regulate mammary development, but the consequent transcriptional changes and cell fate decisions are largely undefined. We show that knockout of the prolactin-regulated Ets transcription factor Elf5 prevented formation of the secretory epithelium during pregnancy. Conversely, overexpression of Elf5 in an inducible transgenic model caused alveolar differentiation and milk secretion in virgin mice, disrupting ductal morphogenesis. CD61+ luminal progenitor cells accumulated in Elf5-deficient mammary glands and were diminished in glands with Elf5 overexpression. Thus Elf5 specifies the differentiation of CD61+ progenitors to establish the secretory alveolar lineage during pregnancy, providing a link between prolactin, transcriptional events, and alveolar development.

4 May 2015 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KBKatrina Blazek
Katrina Blazek
HEHayley L. Eames
Hayley L. Eames
MWMiriam Weiss
Miriam Weiss
ABAdam J. Byrne
Adam J. Byrne
DPDany Perocheau
Dany Perocheau
IUIrina A. Udalova
Irina A. Udalova
The most studied biological role of type III interferons (IFNs) has so far been their antiviral activity, but their role in autoimmune and inflammatory diseases remains largely unexplored. Here, we show that treatment with IFN-λ2/IL-28A completely halts and reverses the development of collagen-induced arthritis (CIA) and discover cellular and molecular mechanisms of IL-28A antiinflammatory function. We demonstrate that treatment with IL-28A dramatically reduces numbers of proinflammatory IL-17–producing Th17 and γδ T cells in the joints and inguinal lymph nodes, without affecting T cell proliferative responses or levels of anticollagen antibodies. IL-28A exerts its antiinflammatory effect by restricting recruitment of IL-1b–expressing neutrophils, which are important for amplification of inflammation. We identify neutrophils as cells expressing high levels of IFN-λ receptor 1 (IFNLR1)–IL-28 receptor α (IL28RA) and targeted by IL-28A. Our data highlight neutrophils as contributors to the pathogenesis of autoimmune arthritis and present IFN-λs or agonists of IFNLR1–IL28RA as putative new therapeutics for neutrophil-driven inflammation.

1 January 2021 in Kidney International
Verified
Journal Article
Closed access
KBKatrina Blazek
Katrina Blazek
AZAnita van Zwieten
Anita van Zwieten
VSValeria Saglimbene
Valeria Saglimbene
ATArmando Teixeira-Pinto
Armando Teixeira-Pinto

1 June 2013 in Immunity
Verified
Journal Article
Closed access
CFCarlos del Fresno
Carlos del Fresno
DSDidier Soulat
Didier Soulat
SRSusanne Roth
Susanne Roth
KBKatrina Blazek
Katrina Blazek
IUIrina Udalova
Irina Udalova
CACarlos Ardavín
Carlos Ardavín

4 May 2015 in Nature Medicine
Verified
Journal Article
Closed access
EDElise Dalmas
Elise Dalmas
ATAmine Toubal
Amine Toubal
FAFawaz Alzaid
Fawaz Alzaid
KBKatrina Blazek
Katrina Blazek
HEHayley L Eames
Hayley L Eames
NVNicolas Venteclef
Nicolas Venteclef